Healthcare
IBA announces the launch of the development of the world’s first cyclotron-based carbon therapy system in Caen, France through its subsidiary Normandy Hadrontherapy, in collaboration with the Normandy Region and several other private and public players, including SAPHYN.
OECD estimates non adherence to pill regimes cause 200,000 premature deaths a year in EU and costs EUR 125 billion in the US $105 billion in US
Scott Gottlieb, the former commissioner of the U.S. Food and Drug Administration, has joined the board of directors of health-tech company Aetion. This marks the second board of directors the former FDA head has joined this week.
Oncoceutics, a clinical-stage drug discovery and development company, commemorates National Childhood Cancer Awareness Month this September and reiterates its support for children and all those affected by childhood cancer.
Key Opinion Leaders in the field of Proton Therapy shared their latest insights and research on FLASH1 irradiation during IBA’s 3rd Victoria Consortium Meeting and IBA’s symposium on Proton Therapy
Mologic Ltd announced that it has finished recruitment to a major clinical trial with University College London Hospitals (UCLH) to evaluate the Company’s point-of-care (POC) diagnostic test for the early detection of sepsis.
Oncoceutics, Inc. announced a scientific publication in the Journal of Neuro-Oncology describing a complete response and other forms of clinical benefit in pediatric and adult H3 K27M-mutant glioma patients treated with ONC201 on expanded access protocols.
Reston Hospital Center has performed its first blue light cystoscopy procedure – a new technology used to detect non-muscle invasive bladder cancer.
Cyclotron to be dedicated to the production of radiopharmaceuticals for diagnosing and treating critical illnesses worldwide
DCprime Initiates Research Collaboration with the University Medical Center of Groningen on Relapse Vaccine Approach for Ovarian Cancer
PRESS RELEASES